Skip to main content

/ health information/ Group items tagged AstraZeneca-respiratory-inhalers

Group items tagged

Filter: All | Bookmarks | Topics Simple Middle

C4X Discovery signs $400m deal with AstraZeneca - 0 views

www.pharmacy.biz/atment-of-respiratory-diseases

pharmacy-business AstraZeneca-respiratory-Biologics AstraZeneca-respiratory-inhalers AstraZeneca-Respiratory-pipeline NRF2-Activator-programme

shared by pharmacybiz on 28 Nov 22 - No Cached

pharmacybiz on 28 Nov 22

British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme. The Manchester-based company said on Monday (November 28) it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation of any treatment.

<div class="cArrow"> </div><div class="cContentInner">British drug discovery company C4X Discovery said AstraZeneca had signed a licence worth up $402 million to develop an oral therapy for the treatment of inflammatory and respiratory diseases using its NRF2 Activator programme. The Manchester-based company said on Monday (November 28) it would receive pre-clinical milestone payments worth up to $16 million ahead of the first clinical trial, including $2 million upfront. In addition, C4XD said it would receive a further potential $385.8 million in clinical development and commercial milestones and tiered mid-single digit royalties upon commercialisation of any treatment.</div>

...

Cancel

1 - 1 of 1

Showing 20▼ items per page

Related searches